董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Denise Scots Knight | 女 | Chief Executive Officer and Director | 59 | 74.78万 | 未持股 | 2019-04-29 |
| Peter Bains | 男 | Director | 61 | 4.40万 | 未持股 | 2019-04-29 |
| Paul Blackburn | 男 | Director | 64 | 4.80万 | 未持股 | 2019-04-29 |
| Anders Ekblom | 男 | Director | 64 | 4.80万 | 未持股 | 2019-04-29 |
| Kunal Kashyap | 男 | Director | 54 | 4.00万 | 未持股 | 2019-04-29 |
| Deepika R. Pakianathan | -- | Director | 54 | 未披露 | 未持股 | 2019-04-29 |
| Deepika R. Pakianathan | 女 | Director | 54 | 未披露 | 未持股 | 2019-04-29 |
| Deepika R. Pakianathan | 男 | Director | 54 | 未披露 | 未持股 | 2019-04-29 |
| Peter Fellner | 男 | Chairman of the Board | 75 | 10.00万 | 未持股 | 2019-04-29 |
| Michael S. Wyzga | 男 | Director | 64 | 未披露 | 未持股 | 2019-04-29 |
| Richard Jones | 男 | Chief Financial Officer and Director | 52 | 50.15万 | 未持股 | 2019-04-29 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Denise Scots Knight | 女 | Chief Executive Officer and Director | 59 | 74.78万 | 未持股 | 2019-04-29 |
| Alastair MacKinnon | 男 | Chief Medical Officer | 48 | 53.76万 | 未持股 | 2019-04-29 |
| John Richard | 男 | Head of Corporate Development | 61 | 50.79万 | 未持股 | 2019-04-29 |
| Charles Sermon | 男 | General Counsel | 49 | 54.35万 | 未持股 | 2019-04-29 |
| Alexandra Hughes Wilson | 女 | Head of Patient Access and Commercial Planning | 47 | 10.01万 | 未持股 | 2019-04-29 |
| Richard Jones | 男 | Chief Financial Officer and Director | 52 | 50.15万 | 未持股 | 2019-04-29 |
董事简历
中英对照 | 中文 | 英文- Denise Scots Knight
-
Denise Scots Knight，她一直担任我们的董事会成员（2016年11月交易完成以来）。她也曾任职Albireo公司的董事会（2008年2月以来）。2015年7月以来，她曾一直担任Mereo BioPharma Group plc（英国专业生物制药公司）的首席执行官。2010年12月至2015年7月，她担任Phase4 Partners（一个风险资本公司代表Nomura European Investments和Harbourvest管理基金）的管理合伙人。从2004年4月到2010年12月，她是Phase4 Partners（一个领先的日本金融机构Nomura International plc，的风险投资附属机构）的负责人。她此前曾任职Oncomed Pharmaceuticals, Inc（一个公开上市的生物技术公司）的董事会（2008年10月以来）。她目前担任Nabriva Therapeutics（公开上市的生物技术公司）的董事会主席，在那里她也曾担任提名和治理委员会的主席，以及审计委员会的成员。她曾任职于Idenix Pharmaceuticals, Inc（公开上市的生物技术公司）的董事会，在那里她也曾担任审计委员会的成员、提名和公司治理委员会的主席（2003年至2014年8月公司被Merck公司收购）。她持有the University of Birmingham（位于英国）的荣誉学士学位和哲学博士学位，也曾担任加州大学伯克利分校（the University of California, Berkeley）的富布莱特学者。斯科特·奈特博士拥有理学学士学位(荣誉）和博士学位。来自伯明翰大学。
Denise Scots Knight, PhD, co-founded and is the Chief Executive Officer and member of the board of Mereo BioPharma Group plc, a specialty biopharmaceutical Company, positions she has held since 2015. Dr. Scots-Knight has more than 25 years of experience in the biopharmaceutical industry, working in research and development management and as a venture capitalist. From 2010 until 2015 Dr. Scots-Knight was the Managing Partner of Phase4 Partners Ltd., a global life science venture capital firm. From 2004 to 2010 Dr. Scots-Knight was head of Nomura Phase4 Ventures, a venture capital affiliate of Nomura International plc, a leading Japanese financial institution. Dr. Scots-Knight has served on the boards of directors of Oncomed Pharmaceuticals, Inc., Idenix Pharmaceuticals, Inc., Nabriva Therapeutics AG, and AlbireO. Additionally, Dr. Scots-Knight has been named one of the 15 leading women in European biotech by Labiotech UG. - Denise Scots Knight，她一直担任我们的董事会成员（2016年11月交易完成以来）。她也曾任职Albireo公司的董事会（2008年2月以来）。2015年7月以来，她曾一直担任Mereo BioPharma Group plc（英国专业生物制药公司）的首席执行官。2010年12月至2015年7月，她担任Phase4 Partners（一个风险资本公司代表Nomura European Investments和Harbourvest管理基金）的管理合伙人。从2004年4月到2010年12月，她是Phase4 Partners（一个领先的日本金融机构Nomura International plc，的风险投资附属机构）的负责人。她此前曾任职Oncomed Pharmaceuticals, Inc（一个公开上市的生物技术公司）的董事会（2008年10月以来）。她目前担任Nabriva Therapeutics（公开上市的生物技术公司）的董事会主席，在那里她也曾担任提名和治理委员会的主席，以及审计委员会的成员。她曾任职于Idenix Pharmaceuticals, Inc（公开上市的生物技术公司）的董事会，在那里她也曾担任审计委员会的成员、提名和公司治理委员会的主席（2003年至2014年8月公司被Merck公司收购）。她持有the University of Birmingham（位于英国）的荣誉学士学位和哲学博士学位，也曾担任加州大学伯克利分校（the University of California, Berkeley）的富布莱特学者。斯科特·奈特博士拥有理学学士学位(荣誉）和博士学位。来自伯明翰大学。
- Denise Scots Knight, PhD, co-founded and is the Chief Executive Officer and member of the board of Mereo BioPharma Group plc, a specialty biopharmaceutical Company, positions she has held since 2015. Dr. Scots-Knight has more than 25 years of experience in the biopharmaceutical industry, working in research and development management and as a venture capitalist. From 2010 until 2015 Dr. Scots-Knight was the Managing Partner of Phase4 Partners Ltd., a global life science venture capital firm. From 2004 to 2010 Dr. Scots-Knight was head of Nomura Phase4 Ventures, a venture capital affiliate of Nomura International plc, a leading Japanese financial institution. Dr. Scots-Knight has served on the boards of directors of Oncomed Pharmaceuticals, Inc., Idenix Pharmaceuticals, Inc., Nabriva Therapeutics AG, and AlbireO. Additionally, Dr. Scots-Knight has been named one of the 15 leading women in European biotech by Labiotech UG.
- Peter Bains
-
Peter Bains自2015年7月起担任Mereo董事会成员。Bains先生一直担任生物技术公司Sosei Group Corporation的代表执行官兼首席执行官，直到2018年12月31日。此前，他曾担任Syngene International Ltd.（Syngene&8221；）的首席执行官，也曾担任非执行董事（直到2016年）。Bains先生目前担任Phase4和Mina Therapeutics Ltd.的非执行董事。Bains先生一直担任Fermenta Biotech Ltd.的非执行主席，直到2018年4月。Bains先生拥有学士学位。（荣誉。（谢菲尔德大学）。
Peter Bains has served on the Mereo Board since July 2015. Mr. Bains was Representative Executive Officer and Chief Executive Officer of Sosei Group Corporation, a biotechnology company until 31 December 2018. Previously, he was Chief Executive Officer of Syngene International Ltd. “Syngene”, and served as a Non-Executive Director until 2016. Mr. Bains currently serves as Non-Executive Director for Phase4 and MiNA Therapeutics Ltd. Mr. Bains served as Non-Executive Chairman of Fermenta Biotech Ltd. until April 2018. Mr. Bains holds a B.Sc. (Hons.) from Sheffield University. - Peter Bains自2015年7月起担任Mereo董事会成员。Bains先生一直担任生物技术公司Sosei Group Corporation的代表执行官兼首席执行官，直到2018年12月31日。此前，他曾担任Syngene International Ltd.（Syngene&8221；）的首席执行官，也曾担任非执行董事（直到2016年）。Bains先生目前担任Phase4和Mina Therapeutics Ltd.的非执行董事。Bains先生一直担任Fermenta Biotech Ltd.的非执行主席，直到2018年4月。Bains先生拥有学士学位。（荣誉。（谢菲尔德大学）。
- Peter Bains has served on the Mereo Board since July 2015. Mr. Bains was Representative Executive Officer and Chief Executive Officer of Sosei Group Corporation, a biotechnology company until 31 December 2018. Previously, he was Chief Executive Officer of Syngene International Ltd. “Syngene”, and served as a Non-Executive Director until 2016. Mr. Bains currently serves as Non-Executive Director for Phase4 and MiNA Therapeutics Ltd. Mr. Bains served as Non-Executive Chairman of Fermenta Biotech Ltd. until April 2018. Mr. Bains holds a B.Sc. (Hons.) from Sheffield University.
- Paul Blackburn
-
Paul Blackburn自2015年10月起担任Mereo董事会成员。Blackburn先生是葛兰素史克（GlaxoSmithKline）的战略财务项目高级副总裁和财务总监。Blackburn先生目前在Syngene的董事会任职。Blackburn先生是特许管理会计师协会（Chartered Institute of Management Accountants）的成员。Blackburn先生拥有学士学位。来自沃里克大学。
Paul Blackburn has served on the Mereo Board since October 2015. Mr. Blackburn was Senior Vice President Strategic Finance Projects and Financial Controller at GlaxoSmithKline. Mr. Blackburn currently serves on the Board of Directors of Syngene. Mr. Blackburn is a member of the Chartered Institute of Managed Accountants. Mr. Blackburn holds a B.Sc. from Warwick University. - Paul Blackburn自2015年10月起担任Mereo董事会成员。Blackburn先生是葛兰素史克（GlaxoSmithKline）的战略财务项目高级副总裁和财务总监。Blackburn先生目前在Syngene的董事会任职。Blackburn先生是特许管理会计师协会（Chartered Institute of Management Accountants）的成员。Blackburn先生拥有学士学位。来自沃里克大学。
- Paul Blackburn has served on the Mereo Board since October 2015. Mr. Blackburn was Senior Vice President Strategic Finance Projects and Financial Controller at GlaxoSmithKline. Mr. Blackburn currently serves on the Board of Directors of Syngene. Mr. Blackburn is a member of the Chartered Institute of Managed Accountants. Mr. Blackburn holds a B.Sc. from Warwick University.
- Anders Ekblom
-
Anders Ekblom自2015年7月起担任Mereo董事会成员。Ekblom博士曾在阿斯利康公司担任多个执行职位，包括执行Vice President全球药物开发、执行Vice President全球药物开发、全球临床开发主管、全球治疗领域主管、全球科学和技术集成主管，以及阿斯利康公司瑞典分公司的首席执行官。他目前担任ELYPTA AB和TFS International AB的董事会主席，以及Alligator Bioscience AB、Anamar AB、婴儿细菌疗法AB和利欧股份Pharma A/S的董事会成员。Ekblom博士是董事会认证的医生，也是卡罗林斯卡学院的副教授。Ekblom博士拥有卡罗林斯卡学院（Karolinska Institutet）的D.D.S.，M.D.和博士学位。
Anders Ekblom has served on the Mereo Board since July 2015. Dr. Ekblom has held a number of executive positions at AstraZeneca, including Executive Vice President Global Drug Development, Executive Vice President Global Medicines Development, Global Head Clinical Development, Global Therapy Area Head, Global Head Science & Technology Integration, and Chief Executive Officer of AstraZeneca AB Sweden. He currently serves as Chairman of the Board of Elypta AB and TFS International AB, and on the boards of directors of Alligator Bioscience AB, AnaMar AB, Infant Bacterial Therapeutics AB and LEO Pharma A/S. Dr. Ekblom is a board-certified medical doctor and an Associate Professor at the Karolinska Institutet. Dr. Ekblom holds a D.D.S., M.D. and Ph.D. from Karolinska Institutet. - Anders Ekblom自2015年7月起担任Mereo董事会成员。Ekblom博士曾在阿斯利康公司担任多个执行职位，包括执行Vice President全球药物开发、执行Vice President全球药物开发、全球临床开发主管、全球治疗领域主管、全球科学和技术集成主管，以及阿斯利康公司瑞典分公司的首席执行官。他目前担任ELYPTA AB和TFS International AB的董事会主席，以及Alligator Bioscience AB、Anamar AB、婴儿细菌疗法AB和利欧股份Pharma A/S的董事会成员。Ekblom博士是董事会认证的医生，也是卡罗林斯卡学院的副教授。Ekblom博士拥有卡罗林斯卡学院（Karolinska Institutet）的D.D.S.，M.D.和博士学位。
- Anders Ekblom has served on the Mereo Board since July 2015. Dr. Ekblom has held a number of executive positions at AstraZeneca, including Executive Vice President Global Drug Development, Executive Vice President Global Medicines Development, Global Head Clinical Development, Global Therapy Area Head, Global Head Science & Technology Integration, and Chief Executive Officer of AstraZeneca AB Sweden. He currently serves as Chairman of the Board of Elypta AB and TFS International AB, and on the boards of directors of Alligator Bioscience AB, AnaMar AB, Infant Bacterial Therapeutics AB and LEO Pharma A/S. Dr. Ekblom is a board-certified medical doctor and an Associate Professor at the Karolinska Institutet. Dr. Ekblom holds a D.D.S., M.D. and Ph.D. from Karolinska Institutet.
- Kunal Kashyap
-
Kunal Kashyap自2015年7月起担任Mereo董事会成员。Kashyap先生是Allegro Capital Advisors公司的董事长兼总经理，也是葛兰素史克消费者梦百合有限公司的独立董事和Phase4公司的非执行董事。Kashyap先生是Arthur Andersen的合伙人，负责建立和管理他们在印度南部的业务。Kashyap先生也是Celstream Technologies Private Limited的创始人和执行董事。Kashyap先生是印度特许会计师协会（Institute of Chartered Accountants of India）的特许会计师。
Kunal Kashyap has served on the Mereo Board since July 2015. Mr. Kashyap is Chairman and Managing Director of Allegro Capital Advisors and also serves as an Independent Director of GlaxoSmithKline Consumer Healthcare Ltd and a Non-Executive Director of Phase4. Mr. Kashyap was a partner with Arthur Andersen responsible for establishing and managing their operations in South India. Mr. Kashyap is also the Founder and was the Executive Director of Celstream Technologies Private Limited. Mr. Kashyap is a Chartered Accountant from the Institute of Chartered Accountants of India. - Kunal Kashyap自2015年7月起担任Mereo董事会成员。Kashyap先生是Allegro Capital Advisors公司的董事长兼总经理，也是葛兰素史克消费者梦百合有限公司的独立董事和Phase4公司的非执行董事。Kashyap先生是Arthur Andersen的合伙人，负责建立和管理他们在印度南部的业务。Kashyap先生也是Celstream Technologies Private Limited的创始人和执行董事。Kashyap先生是印度特许会计师协会（Institute of Chartered Accountants of India）的特许会计师。
- Kunal Kashyap has served on the Mereo Board since July 2015. Mr. Kashyap is Chairman and Managing Director of Allegro Capital Advisors and also serves as an Independent Director of GlaxoSmithKline Consumer Healthcare Ltd and a Non-Executive Director of Phase4. Mr. Kashyap was a partner with Arthur Andersen responsible for establishing and managing their operations in South India. Mr. Kashyap is also the Founder and was the Executive Director of Celstream Technologies Private Limited. Mr. Kashyap is a Chartered Accountant from the Institute of Chartered Accountants of India.
- Deepika R. Pakianathan
-
合并完成后，DeepikaR.Pakianathan自2019年4月起担任Mereo董事会成员，并自2008年12月起担任Oncomed董事，直至合并完成。Pakianathan自2001年起担任Delphi Ventures（一家风险投资公司，专注于生物技术和医疗设备投资）管理成员。Pakianathan博士任职于AlderBiopharmaceuticals，Inc.公司、Karyopharm Therapeutics公司和CalitheraBiosciences，Inc.公司的董事会。Pakianathan博士曾担任AlexzaPharmaceuticals，Inc.、PtcTherapeutics，Inc.和Relypsa，Inc.的董事会成员Pakianathan博士获得了理学学士学位。印度孟买大学工商管理硕士学位。拥有印度孟买大学癌症研究所的硕士学位和威克森林大学的博士学位。
Deepika R. Pakianathan has served on the Mereo Board since April 2019 following completion of the Merger and served as a director of OncoMed since December 2008 until the closing of the Merger. Since 2001 Dr. Pakianathan has been a Managing Member at Delphi Ventures, a venture capital firm focused on biotechnology and medical device investments. Dr. Pakianathan serves on the boards of directors of Alder Biopharmaceuticals, Inc., Karyopharm Therapeutics, Inc., and Calithera Biosciences, Inc. Dr. Pakianathan previously served on the boards of directors of Alexza Pharmaceuticals, Inc., PTC Therapeutics, Inc. and Relypsa, Inc. Dr. Pakianathan received a B.Sc. from the University of Bombay, India, a M.Sc. from The Cancer Research Institute at the University of Bombay, India, and an M.S. and Ph.D. from Wake Forest University. - 合并完成后，DeepikaR.Pakianathan自2019年4月起担任Mereo董事会成员，并自2008年12月起担任Oncomed董事，直至合并完成。Pakianathan自2001年起担任Delphi Ventures（一家风险投资公司，专注于生物技术和医疗设备投资）管理成员。Pakianathan博士任职于AlderBiopharmaceuticals，Inc.公司、Karyopharm Therapeutics公司和CalitheraBiosciences，Inc.公司的董事会。Pakianathan博士曾担任AlexzaPharmaceuticals，Inc.、PtcTherapeutics，Inc.和Relypsa，Inc.的董事会成员Pakianathan博士获得了理学学士学位。印度孟买大学工商管理硕士学位。拥有印度孟买大学癌症研究所的硕士学位和威克森林大学的博士学位。
- Deepika R. Pakianathan has served on the Mereo Board since April 2019 following completion of the Merger and served as a director of OncoMed since December 2008 until the closing of the Merger. Since 2001 Dr. Pakianathan has been a Managing Member at Delphi Ventures, a venture capital firm focused on biotechnology and medical device investments. Dr. Pakianathan serves on the boards of directors of Alder Biopharmaceuticals, Inc., Karyopharm Therapeutics, Inc., and Calithera Biosciences, Inc. Dr. Pakianathan previously served on the boards of directors of Alexza Pharmaceuticals, Inc., PTC Therapeutics, Inc. and Relypsa, Inc. Dr. Pakianathan received a B.Sc. from the University of Bombay, India, a M.Sc. from The Cancer Research Institute at the University of Bombay, India, and an M.S. and Ph.D. from Wake Forest University.
- Deepika R. Pakianathan
-
Deepika R. Pakianathan，博士，自2020年7月起担任Theravance Biopharma, Inc.的董事。2001年以来，她一直担任Delphi Ventures（风险投资公司）的管理成员。她也是Redd Pharmaceuticals, Inc.（一家私营制药公司）的首席执行官（2019年9月以来）。从2007年到2019年，她担任Alder Pharmaceuticals, Inc.的董事会成员。从2004年到2016年，她担任Alexza Pharmaceuticals, Inc.的董事会成员。从1998年到2001年，Pakianathan博士担任JP Morgan Chase & Company的医疗保健集团副总裁。从1993年到1997年，她担任Genentech Corporation免疫学系的博士后科学家。她目前担任Calithera Biosciences, Inc.、Karyopharm Therapeutics, Inc.、Mereo Biopharma Group PLC和FS Development Corp. II （SPAC）的董事会成员。她持有维克森林大学（Wake Forest University）的硕士学位和博士学位，印度孟买大学（the University of Bombay）的学士学位，以及印度孟买大学（the University of Bombay）癌症研究所（the Cancer Research Institute）的硕士学位。
Deepika R. Pakianathan, Ph.D., has served as a member of Theravance Biopharma, Inc. board of directors since July 2020. Since 2001 Dr. Pakianathan has served as a Managing Member at Delphi Ventures, a venture capital firm. She is also the Chief Executive Officer of Redd Pharmaceuticals, Inc., a privately-held pharmaceuticals company, since September 2019. From 2007 to 2019 Dr. Pakianathan served on the board of directors of Alder Pharmaceuticals, Inc. and from 2004 to 2016 Dr. Pakianathan served on the board of directors of Alexza Pharmaceuticals, Inc. From 1998 to 2001 Dr. Pakianathan served as a Vice President in the healthcare group at JP Morgan Chase & Company. From 1993 to 1997 Dr. Pakianathan served as a postdoctoral scientist in the Immunology Department at Genentech Corporation. Dr. Pakianathan currently serves on the board of directors of Calithera Biosciences, Inc., Karyopharm Therapeutics, Inc., Mereo Biopharma Group PLC and FS Development Corp. II, an SPAC. Dr. Pakianathan holds an M.S. and a Ph.D. from Wake Forest University, a B.Sc. from the University of Bombay, India and an M.Sc. from The Cancer Research Institute at the University of Bombay, India. - Deepika R. Pakianathan，博士，自2020年7月起担任Theravance Biopharma, Inc.的董事。2001年以来，她一直担任Delphi Ventures（风险投资公司）的管理成员。她也是Redd Pharmaceuticals, Inc.（一家私营制药公司）的首席执行官（2019年9月以来）。从2007年到2019年，她担任Alder Pharmaceuticals, Inc.的董事会成员。从2004年到2016年，她担任Alexza Pharmaceuticals, Inc.的董事会成员。从1998年到2001年，Pakianathan博士担任JP Morgan Chase & Company的医疗保健集团副总裁。从1993年到1997年，她担任Genentech Corporation免疫学系的博士后科学家。她目前担任Calithera Biosciences, Inc.、Karyopharm Therapeutics, Inc.、Mereo Biopharma Group PLC和FS Development Corp. II （SPAC）的董事会成员。她持有维克森林大学（Wake Forest University）的硕士学位和博士学位，印度孟买大学（the University of Bombay）的学士学位，以及印度孟买大学（the University of Bombay）癌症研究所（the Cancer Research Institute）的硕士学位。
- Deepika R. Pakianathan, Ph.D., has served as a member of Theravance Biopharma, Inc. board of directors since July 2020. Since 2001 Dr. Pakianathan has served as a Managing Member at Delphi Ventures, a venture capital firm. She is also the Chief Executive Officer of Redd Pharmaceuticals, Inc., a privately-held pharmaceuticals company, since September 2019. From 2007 to 2019 Dr. Pakianathan served on the board of directors of Alder Pharmaceuticals, Inc. and from 2004 to 2016 Dr. Pakianathan served on the board of directors of Alexza Pharmaceuticals, Inc. From 1998 to 2001 Dr. Pakianathan served as a Vice President in the healthcare group at JP Morgan Chase & Company. From 1993 to 1997 Dr. Pakianathan served as a postdoctoral scientist in the Immunology Department at Genentech Corporation. Dr. Pakianathan currently serves on the board of directors of Calithera Biosciences, Inc., Karyopharm Therapeutics, Inc., Mereo Biopharma Group PLC and FS Development Corp. II, an SPAC. Dr. Pakianathan holds an M.S. and a Ph.D. from Wake Forest University, a B.Sc. from the University of Bombay, India and an M.Sc. from The Cancer Research Institute at the University of Bombay, India.
- Deepika R. Pakianathan
-
Deepika R. Pakianathan， 2004年11月以来，担任我们的董事会的成员。自2001年以来，他德尔福合资企业担任管理成员，该公司为风险资本公司，专注于医疗投资。从1998年到2001年，他担任JPMorgan的生物技术高级银行家。加入JPMorgan之前，从1997年到1998年，他是创世纪商人集团的私人投资伙伴关系研究分析师；从1993年到1997年，他担任基因泰克公司的博士后科学家。从2013年4月到现在，他也是Karyopharm Therapeutics公司的董事会成员，该公司为上市医药公司。从2008年12月到现在，他担任OncoMed制药公司的董事会成员，该公司为一家公开上市的生物制药公司。Pakianathan获得了维克森林大学的免疫学博士学位和生物学硕士学位，以及孟买大学的生物物理学商科硕士学位和运筹学学位。
Deepika R. Pakianathan has served as a member of the Board since November 2004. Since 2001 Dr. Pakianathan has served as a managing member at Delphi Ventures, a venture capital firm focusing on healthcare investments. From 1998 to 2001 Dr. Pakianathan was a senior biotechnology banker at JPMorgan. Prior to joining JPMorgan, Dr. Pakianathan was a research analyst at Genesis Merchant Group, a private investment partnership, from 1997 to 1998 and a post-doctoral scientist at Genentech, Inc. from 1993 to 1997. Dr. Pakianathan has served on the board of directors of Karyopharm Therapeutics, Inc., a publicly traded pharmaceutical company, since April 2013 and OncoMed Pharmaceuticals Inc., a publicly traded biopharmaceutical company since December 2008. - Deepika R. Pakianathan， 2004年11月以来，担任我们的董事会的成员。自2001年以来，他德尔福合资企业担任管理成员，该公司为风险资本公司，专注于医疗投资。从1998年到2001年，他担任JPMorgan的生物技术高级银行家。加入JPMorgan之前，从1997年到1998年，他是创世纪商人集团的私人投资伙伴关系研究分析师；从1993年到1997年，他担任基因泰克公司的博士后科学家。从2013年4月到现在，他也是Karyopharm Therapeutics公司的董事会成员，该公司为上市医药公司。从2008年12月到现在，他担任OncoMed制药公司的董事会成员，该公司为一家公开上市的生物制药公司。Pakianathan获得了维克森林大学的免疫学博士学位和生物学硕士学位，以及孟买大学的生物物理学商科硕士学位和运筹学学位。
- Deepika R. Pakianathan has served as a member of the Board since November 2004. Since 2001 Dr. Pakianathan has served as a managing member at Delphi Ventures, a venture capital firm focusing on healthcare investments. From 1998 to 2001 Dr. Pakianathan was a senior biotechnology banker at JPMorgan. Prior to joining JPMorgan, Dr. Pakianathan was a research analyst at Genesis Merchant Group, a private investment partnership, from 1997 to 1998 and a post-doctoral scientist at Genentech, Inc. from 1993 to 1997. Dr. Pakianathan has served on the board of directors of Karyopharm Therapeutics, Inc., a publicly traded pharmaceutical company, since April 2013 and OncoMed Pharmaceuticals Inc., a publicly traded biopharmaceutical company since December 2008.
- Peter Fellner
-
Peter Fellner自2011年7月以来担任副主席。此前他从2002年到2011年7月担任Astex Therapeutics Limited的主席。他还担任Consort Medical plc, Optos plc, Biotie Therapies Corp和Vernalis plc的董事长。此外，他是全球生物制药公司UCB SA的董事，是the Novo A/S Advisory Group的成员。他担任其他生命科学公司的主席，包括Acambis plc和Premier Research Group plc，直到它们每个在2008年售出。他以前担任Celltech Group plc（欧洲最大的生物技术公司之一）的主席直到2004年收购，从1990年到2003年担任其首席执行官。加入Celltech之前，他从1986年到1990年担任Roche UK的首席执行官。从1984年到1986年他是the Roche UK Research Centre的董事。
Peter Fellner has been Chairman of the Mereo Board since July 2015. He also serves as Chairman of the board of directors of Consort Medical plc, and was Chairman of the board of directors of Ablynx NV from November 2013 until January 2018 and Vernalis plc until October 2018. Dr. Fellner was previously Chairman of the board of directors of Acambis plc from 2006 until its acquisition by Sanofi Pasteur and Optos plc from 2000 until its acquisition by Nikon Corporation, and Vice Chairman of Astex Pharmaceuticals Inc. until its acquisition by Otsuka Pharmaceutical Company. He also served as a Director of UCB SA and was CEO and then Chairman of Celltech Group plc. Dr. Fellner holds a B.Sc. Hons. from the University of Sheffield and a Ph.D. from the University of Cambridge. - Peter Fellner自2011年7月以来担任副主席。此前他从2002年到2011年7月担任Astex Therapeutics Limited的主席。他还担任Consort Medical plc, Optos plc, Biotie Therapies Corp和Vernalis plc的董事长。此外，他是全球生物制药公司UCB SA的董事，是the Novo A/S Advisory Group的成员。他担任其他生命科学公司的主席，包括Acambis plc和Premier Research Group plc，直到它们每个在2008年售出。他以前担任Celltech Group plc（欧洲最大的生物技术公司之一）的主席直到2004年收购，从1990年到2003年担任其首席执行官。加入Celltech之前，他从1986年到1990年担任Roche UK的首席执行官。从1984年到1986年他是the Roche UK Research Centre的董事。
- Peter Fellner has been Chairman of the Mereo Board since July 2015. He also serves as Chairman of the board of directors of Consort Medical plc, and was Chairman of the board of directors of Ablynx NV from November 2013 until January 2018 and Vernalis plc until October 2018. Dr. Fellner was previously Chairman of the board of directors of Acambis plc from 2006 until its acquisition by Sanofi Pasteur and Optos plc from 2000 until its acquisition by Nikon Corporation, and Vice Chairman of Astex Pharmaceuticals Inc. until its acquisition by Otsuka Pharmaceutical Company. He also served as a Director of UCB SA and was CEO and then Chairman of Celltech Group plc. Dr. Fellner holds a B.Sc. Hons. from the University of Sheffield and a Ph.D. from the University of Cambridge.
- Michael S. Wyzga
-
Michael S. Wyzga，他是我们董事会的成员（自2013年11月以来）。从2011年12月至2013年11月，他担任总裁兼首席执行官，他是Radius Health, Inc.（一个上市的生物制药公司）的董事会成员。此前，他在美国健赞（Genzyme Corporation）（上市的全球生物科技公司）担任许多职务。他于1998年2月加入美国健赞（Genzyme Corporation）并担任其执行副总裁负责财务（2003年5月到2011年11月）和首席财务官（1999年7月至2011年11月）。另外，他在我们董事会任职。他是Idenix Pharmaceuticals, Inc.（一个上市的生物科技公司）的董事会成员，他还是其薪酬委员会成员和审计委员会主席。自2014年2月以来，他担任Akebia Therapeutics, Inc.（一个上市的生物制药公司）的董事会成员，他担任其提名和治理委员会成员和审计委员会主席。他曾担任阿尔特斯制药公司（Altus Pharmaceuticals, Inc.）（一个上市的生物制药公司并于2009年11月停止运营）的董事会成员。他获得普罗维登斯学院（Providence College）的工商管理硕士学位和萨福克大学 （Suffolk University）的学士学位。
Michael S. Wyzga has served as a member of our board of directors since the closing of the Merger in March 2019. Prior to the Merger, Mr. Wyzga served as Chairman of the X4 board of directors since July 2018. Mr. Wyzga is currently the President of MSW Consulting Inc., a strategic consulting group focused in the life sciences area. From December 2011 until November 2013 Mr. Wyzga served as President and Chief Executive Officer and a member of the board of directors of Radius Health, Inc., a publicly traded biopharmaceutical company. Prior to that, Mr. Wyzga served in various senior management positions at Genzyme Corporation, a publicly traded global biotechnology company. Mr. Wyzga joined Genzyme in February 1998 and most recently served as Executive Vice President, Finance from May 2003 until November 2011 and as chief financial officer from July 1999 until November 2011. From February 2014 to December 2018 Mr. Wyzga served as a member of the board of directors of Akebia Therapeutics, Inc., a publicly traded biopharmaceutical company, where he was also a member of the compensation committee and chair of the audit committee. Since February 2015 Mr. Wyzga has also served as a member of the board of directors of Exact Sciences Corporation, a publicly traded medical technology company, where he is also a member of the audit and compensation committees. From October 2013 until Oncomed Pharmaceuticals, Inc.’s business combination with Mereo BioPharma Group plc in April 2019 Mr. Wyzga served as a member of the board of directors of Oncomed Pharmaceuticals, Inc., where he was also a member of the audit committee. Since February 2016 Mr. Wyzga has also served as Chairman of the board of directors of GenSight Biologics S.A., a Euronext traded biopharmaceutical company. Mr. Wyzga also previously served as a member of the board of directors of Idenix Pharmaceuticals, Inc., a publicly traded biotechnology company that was acquired by Merck in August 2014 where he also served as the chair of the audit committee and a member of the compensation committee, and as a member of the Supervisory Board of Prosensa Holding B.V., a publicly traded biopharmaceutical company, from June 2014 until the Prosensa acquisition by BioMarin Falcon B.V. in December 2014. He received an M.B.A. from Providence College and a B.S. from Suffolk University. - Michael S. Wyzga，他是我们董事会的成员（自2013年11月以来）。从2011年12月至2013年11月，他担任总裁兼首席执行官，他是Radius Health, Inc.（一个上市的生物制药公司）的董事会成员。此前，他在美国健赞（Genzyme Corporation）（上市的全球生物科技公司）担任许多职务。他于1998年2月加入美国健赞（Genzyme Corporation）并担任其执行副总裁负责财务（2003年5月到2011年11月）和首席财务官（1999年7月至2011年11月）。另外，他在我们董事会任职。他是Idenix Pharmaceuticals, Inc.（一个上市的生物科技公司）的董事会成员，他还是其薪酬委员会成员和审计委员会主席。自2014年2月以来，他担任Akebia Therapeutics, Inc.（一个上市的生物制药公司）的董事会成员，他担任其提名和治理委员会成员和审计委员会主席。他曾担任阿尔特斯制药公司（Altus Pharmaceuticals, Inc.）（一个上市的生物制药公司并于2009年11月停止运营）的董事会成员。他获得普罗维登斯学院（Providence College）的工商管理硕士学位和萨福克大学 （Suffolk University）的学士学位。
- Michael S. Wyzga has served as a member of our board of directors since the closing of the Merger in March 2019. Prior to the Merger, Mr. Wyzga served as Chairman of the X4 board of directors since July 2018. Mr. Wyzga is currently the President of MSW Consulting Inc., a strategic consulting group focused in the life sciences area. From December 2011 until November 2013 Mr. Wyzga served as President and Chief Executive Officer and a member of the board of directors of Radius Health, Inc., a publicly traded biopharmaceutical company. Prior to that, Mr. Wyzga served in various senior management positions at Genzyme Corporation, a publicly traded global biotechnology company. Mr. Wyzga joined Genzyme in February 1998 and most recently served as Executive Vice President, Finance from May 2003 until November 2011 and as chief financial officer from July 1999 until November 2011. From February 2014 to December 2018 Mr. Wyzga served as a member of the board of directors of Akebia Therapeutics, Inc., a publicly traded biopharmaceutical company, where he was also a member of the compensation committee and chair of the audit committee. Since February 2015 Mr. Wyzga has also served as a member of the board of directors of Exact Sciences Corporation, a publicly traded medical technology company, where he is also a member of the audit and compensation committees. From October 2013 until Oncomed Pharmaceuticals, Inc.’s business combination with Mereo BioPharma Group plc in April 2019 Mr. Wyzga served as a member of the board of directors of Oncomed Pharmaceuticals, Inc., where he was also a member of the audit committee. Since February 2016 Mr. Wyzga has also served as Chairman of the board of directors of GenSight Biologics S.A., a Euronext traded biopharmaceutical company. Mr. Wyzga also previously served as a member of the board of directors of Idenix Pharmaceuticals, Inc., a publicly traded biotechnology company that was acquired by Merck in August 2014 where he also served as the chair of the audit committee and a member of the compensation committee, and as a member of the Supervisory Board of Prosensa Holding B.V., a publicly traded biopharmaceutical company, from June 2014 until the Prosensa acquisition by BioMarin Falcon B.V. in December 2014. He received an M.B.A. from Providence College and a B.S. from Suffolk University.
- Richard Jones
-
Richard Jones自2017年1月起担任Mereo首席财务官和Mereo董事会成员。从2011年到加入Mereo，琼斯先生是Shield Therapeutics plc的首席财务官兼公司秘书，在那里他还从2010年到2011年担任非执行董事。Jones先生担任Alliance Pharma plc.的董事会非执行董事。Jones先生是英格兰和威尔士特许会计师协会（ICAEW）的合格特许会计师ACA，并持有B.Eng。（荣誉。来自泰恩河畔纽卡斯尔大学。
Richard Jones has served as Mereo’s Chief Financial Officer and as a member of the Mereo Board since January 2017. From 2011 until joining Mereo, Mr. Jones was the Chief Financial Officer and Company Secretary of Shield Therapeutics plc, where he also served as a Non-Executive Director from 2010 to 2011. Mr. Jones serves as a non-executive director on the board of Alliance Pharma plc. Mr. Jones is a qualified chartered accountant ACA with the Institute of Chartered Accountants in England and Wales (ICAEW) and holds a B.Eng. (Hons.) from the University of Newcastle upon Tyne. - Richard Jones自2017年1月起担任Mereo首席财务官和Mereo董事会成员。从2011年到加入Mereo，琼斯先生是Shield Therapeutics plc的首席财务官兼公司秘书，在那里他还从2010年到2011年担任非执行董事。Jones先生担任Alliance Pharma plc.的董事会非执行董事。Jones先生是英格兰和威尔士特许会计师协会（ICAEW）的合格特许会计师ACA，并持有B.Eng。（荣誉。来自泰恩河畔纽卡斯尔大学。
- Richard Jones has served as Mereo’s Chief Financial Officer and as a member of the Mereo Board since January 2017. From 2011 until joining Mereo, Mr. Jones was the Chief Financial Officer and Company Secretary of Shield Therapeutics plc, where he also served as a Non-Executive Director from 2010 to 2011. Mr. Jones serves as a non-executive director on the board of Alliance Pharma plc. Mr. Jones is a qualified chartered accountant ACA with the Institute of Chartered Accountants in England and Wales (ICAEW) and holds a B.Eng. (Hons.) from the University of Newcastle upon Tyne.
高管简历
中英对照 | 中文 | 英文- Denise Scots Knight
Denise Scots Knight，她一直担任我们的董事会成员（2016年11月交易完成以来）。她也曾任职Albireo公司的董事会（2008年2月以来）。2015年7月以来，她曾一直担任Mereo BioPharma Group plc（英国专业生物制药公司）的首席执行官。2010年12月至2015年7月，她担任Phase4 Partners（一个风险资本公司代表Nomura European Investments和Harbourvest管理基金）的管理合伙人。从2004年4月到2010年12月，她是Phase4 Partners（一个领先的日本金融机构Nomura International plc，的风险投资附属机构）的负责人。她此前曾任职Oncomed Pharmaceuticals, Inc（一个公开上市的生物技术公司）的董事会（2008年10月以来）。她目前担任Nabriva Therapeutics（公开上市的生物技术公司）的董事会主席，在那里她也曾担任提名和治理委员会的主席，以及审计委员会的成员。她曾任职于Idenix Pharmaceuticals, Inc（公开上市的生物技术公司）的董事会，在那里她也曾担任审计委员会的成员、提名和公司治理委员会的主席（2003年至2014年8月公司被Merck公司收购）。她持有the University of Birmingham（位于英国）的荣誉学士学位和哲学博士学位，也曾担任加州大学伯克利分校（the University of California, Berkeley）的富布莱特学者。斯科特·奈特博士拥有理学学士学位(荣誉）和博士学位。来自伯明翰大学。
Denise Scots Knight, PhD, co-founded and is the Chief Executive Officer and member of the board of Mereo BioPharma Group plc, a specialty biopharmaceutical Company, positions she has held since 2015. Dr. Scots-Knight has more than 25 years of experience in the biopharmaceutical industry, working in research and development management and as a venture capitalist. From 2010 until 2015 Dr. Scots-Knight was the Managing Partner of Phase4 Partners Ltd., a global life science venture capital firm. From 2004 to 2010 Dr. Scots-Knight was head of Nomura Phase4 Ventures, a venture capital affiliate of Nomura International plc, a leading Japanese financial institution. Dr. Scots-Knight has served on the boards of directors of Oncomed Pharmaceuticals, Inc., Idenix Pharmaceuticals, Inc., Nabriva Therapeutics AG, and AlbireO. Additionally, Dr. Scots-Knight has been named one of the 15 leading women in European biotech by Labiotech UG.- Denise Scots Knight，她一直担任我们的董事会成员（2016年11月交易完成以来）。她也曾任职Albireo公司的董事会（2008年2月以来）。2015年7月以来，她曾一直担任Mereo BioPharma Group plc（英国专业生物制药公司）的首席执行官。2010年12月至2015年7月，她担任Phase4 Partners（一个风险资本公司代表Nomura European Investments和Harbourvest管理基金）的管理合伙人。从2004年4月到2010年12月，她是Phase4 Partners（一个领先的日本金融机构Nomura International plc，的风险投资附属机构）的负责人。她此前曾任职Oncomed Pharmaceuticals, Inc（一个公开上市的生物技术公司）的董事会（2008年10月以来）。她目前担任Nabriva Therapeutics（公开上市的生物技术公司）的董事会主席，在那里她也曾担任提名和治理委员会的主席，以及审计委员会的成员。她曾任职于Idenix Pharmaceuticals, Inc（公开上市的生物技术公司）的董事会，在那里她也曾担任审计委员会的成员、提名和公司治理委员会的主席（2003年至2014年8月公司被Merck公司收购）。她持有the University of Birmingham（位于英国）的荣誉学士学位和哲学博士学位，也曾担任加州大学伯克利分校（the University of California, Berkeley）的富布莱特学者。斯科特·奈特博士拥有理学学士学位(荣誉）和博士学位。来自伯明翰大学。
- Denise Scots Knight, PhD, co-founded and is the Chief Executive Officer and member of the board of Mereo BioPharma Group plc, a specialty biopharmaceutical Company, positions she has held since 2015. Dr. Scots-Knight has more than 25 years of experience in the biopharmaceutical industry, working in research and development management and as a venture capitalist. From 2010 until 2015 Dr. Scots-Knight was the Managing Partner of Phase4 Partners Ltd., a global life science venture capital firm. From 2004 to 2010 Dr. Scots-Knight was head of Nomura Phase4 Ventures, a venture capital affiliate of Nomura International plc, a leading Japanese financial institution. Dr. Scots-Knight has served on the boards of directors of Oncomed Pharmaceuticals, Inc., Idenix Pharmaceuticals, Inc., Nabriva Therapeutics AG, and AlbireO. Additionally, Dr. Scots-Knight has been named one of the 15 leading women in European biotech by Labiotech UG.
- Alastair MacKinnon
Alastair MacKinnon自2015年7月起担任Mereo&；8217；S首席医疗官。从2010年到加入Mereo，他曾担任Phase4公司的合伙人，在那里他目前担任董事会成员。Dr.Mackinnon持有B.SC.以及伦敦国王学院（King&8217；s College London）工商管理硕士学位，是爱丁堡皇家外科医生学院的成员。
Alastair MacKinnon has served as Mereo’s Chief Medical Officer since July 2015. From 2010 until joining Mereo, Dr. MacKinnon was a Partner of Phase4 where he currently serves as a member of the board of directors. Dr. MacKinnon holds a B.Sc. and a MBBS from King’s College London and is a Member of the Royal College of Surgeons in Edinburgh.- Alastair MacKinnon自2015年7月起担任Mereo&；8217；S首席医疗官。从2010年到加入Mereo，他曾担任Phase4公司的合伙人，在那里他目前担任董事会成员。Dr.Mackinnon持有B.SC.以及伦敦国王学院（King&8217；s College London）工商管理硕士学位，是爱丁堡皇家外科医生学院的成员。
- Alastair MacKinnon has served as Mereo’s Chief Medical Officer since July 2015. From 2010 until joining Mereo, Dr. MacKinnon was a Partner of Phase4 where he currently serves as a member of the board of directors. Dr. MacKinnon holds a B.Sc. and a MBBS from King’s College London and is a Member of the Royal College of Surgeons in Edinburgh.
- John Richard
John Richard自2015年7月起担任Mereo&；8217；的企业发展主管。加入Mereo公司之前，他曾担任Nomura公司（全球投资银行）、Phase4的顾问。Richard先生任职于Vaxart，Inc.、Catalyst Biosciences、Que Oncology和Phase4的董事会。Richard先生拥有斯坦福大学（Stanford University）的学士学位和哈佛商学院（Harvard Business School）的工商管理硕士学位。
John Richard has served as Mereo’s Head of Corporate Development since July 2015. Prior to joining Mereo, he was a consultant for Nomura, a global investment bank, and Phase4. Mr. Richard serves on the boards of Vaxart, Inc., Catalyst Biosciences, QUE Oncology, and Phase4. Mr. Richard holds a B.S. from Stanford University and an MBA from Harvard Business School.- John Richard自2015年7月起担任Mereo&；8217；的企业发展主管。加入Mereo公司之前，他曾担任Nomura公司（全球投资银行）、Phase4的顾问。Richard先生任职于Vaxart，Inc.、Catalyst Biosciences、Que Oncology和Phase4的董事会。Richard先生拥有斯坦福大学（Stanford University）的学士学位和哈佛商学院（Harvard Business School）的工商管理硕士学位。
- John Richard has served as Mereo’s Head of Corporate Development since July 2015. Prior to joining Mereo, he was a consultant for Nomura, a global investment bank, and Phase4. Mr. Richard serves on the boards of Vaxart, Inc., Catalyst Biosciences, QUE Oncology, and Phase4. Mr. Richard holds a B.S. from Stanford University and an MBA from Harvard Business School.
- Charles Sermon
Charles Sermon自2015年7月起担任Mereo的总法律顾问兼公司秘书。从2010年到加入Mereo，他曾担任Phase4公司的合伙人，在那里他目前担任董事会成员。Sermon先生在完成律师协会（Law Society）的期末考试后，在Freshfields接受了律师培训并获得律师资格。Sermon先生拥有法学学士学位。荣誉。来自赫尔大学。
Charles Sermon has served as Mereo’s General Counsel and Company Secretary since July 2015. From 2010 until joining Mereo, Mr. Sermon was a Partner of Phase4 where he currently serves as a member of the board of directors. Mr. Sermon trained and qualified as a lawyer with Freshfields after completing the Law Society’s Final Examination. Mr. Sermon holds an LL.B. Hons. from Hull University.- Charles Sermon自2015年7月起担任Mereo的总法律顾问兼公司秘书。从2010年到加入Mereo，他曾担任Phase4公司的合伙人，在那里他目前担任董事会成员。Sermon先生在完成律师协会（Law Society）的期末考试后，在Freshfields接受了律师培训并获得律师资格。Sermon先生拥有法学学士学位。荣誉。来自赫尔大学。
- Charles Sermon has served as Mereo’s General Counsel and Company Secretary since July 2015. From 2010 until joining Mereo, Mr. Sermon was a Partner of Phase4 where he currently serves as a member of the board of directors. Mr. Sermon trained and qualified as a lawyer with Freshfields after completing the Law Society’s Final Examination. Mr. Sermon holds an LL.B. Hons. from Hull University.
- Alexandra Hughes Wilson
Alexandra Hughes Wilson自2018年3月起担任Mereo的患者准入和商业计划主管。在加入Mereo之前，Hughes-Wilson女士是瑞典孤儿BioVitrum Publ的高级副总裁，首席病人接入官。AB，一家生物技术公司，从2012年到2018年以及在此之前，在生物技术公司Genzyme（现称Sanofi Genzyme）担任Vice President健康和市场准入政策EMEA。Hughes-Wilson女士拥有法律和政治学士学位（荣誉）。（来自英国达勒姆大学。
Alexandra Hughes Wilson has served as Mereo’s Head of Patient Access and Commercial Planning since March 2018. Prior to joining Mereo, Ms. Hughes-Wilson was Senior Vice President, Chief Patient Access Officer at Swedish Orphan Biovitrum publ. AB, a biotechnology company, from 2012 to 2018 and prior to that served as Vice President Health & Market Access Policy EMEA at Genzyme (now Sanofi Genzyme), a biotechnology company. Ms. Hughes-Wilson holds a Bachelor’s Degree in Law and Politics (Hons.) from the University of Durham, U.K.- Alexandra Hughes Wilson自2018年3月起担任Mereo的患者准入和商业计划主管。在加入Mereo之前，Hughes-Wilson女士是瑞典孤儿BioVitrum Publ的高级副总裁，首席病人接入官。AB，一家生物技术公司，从2012年到2018年以及在此之前，在生物技术公司Genzyme（现称Sanofi Genzyme）担任Vice President健康和市场准入政策EMEA。Hughes-Wilson女士拥有法律和政治学士学位（荣誉）。（来自英国达勒姆大学。
- Alexandra Hughes Wilson has served as Mereo’s Head of Patient Access and Commercial Planning since March 2018. Prior to joining Mereo, Ms. Hughes-Wilson was Senior Vice President, Chief Patient Access Officer at Swedish Orphan Biovitrum publ. AB, a biotechnology company, from 2012 to 2018 and prior to that served as Vice President Health & Market Access Policy EMEA at Genzyme (now Sanofi Genzyme), a biotechnology company. Ms. Hughes-Wilson holds a Bachelor’s Degree in Law and Politics (Hons.) from the University of Durham, U.K.
- Richard Jones
Richard Jones自2017年1月起担任Mereo首席财务官和Mereo董事会成员。从2011年到加入Mereo，琼斯先生是Shield Therapeutics plc的首席财务官兼公司秘书，在那里他还从2010年到2011年担任非执行董事。Jones先生担任Alliance Pharma plc.的董事会非执行董事。Jones先生是英格兰和威尔士特许会计师协会（ICAEW）的合格特许会计师ACA，并持有B.Eng。（荣誉。来自泰恩河畔纽卡斯尔大学。
Richard Jones has served as Mereo’s Chief Financial Officer and as a member of the Mereo Board since January 2017. From 2011 until joining Mereo, Mr. Jones was the Chief Financial Officer and Company Secretary of Shield Therapeutics plc, where he also served as a Non-Executive Director from 2010 to 2011. Mr. Jones serves as a non-executive director on the board of Alliance Pharma plc. Mr. Jones is a qualified chartered accountant ACA with the Institute of Chartered Accountants in England and Wales (ICAEW) and holds a B.Eng. (Hons.) from the University of Newcastle upon Tyne.- Richard Jones自2017年1月起担任Mereo首席财务官和Mereo董事会成员。从2011年到加入Mereo，琼斯先生是Shield Therapeutics plc的首席财务官兼公司秘书，在那里他还从2010年到2011年担任非执行董事。Jones先生担任Alliance Pharma plc.的董事会非执行董事。Jones先生是英格兰和威尔士特许会计师协会（ICAEW）的合格特许会计师ACA，并持有B.Eng。（荣誉。来自泰恩河畔纽卡斯尔大学。
- Richard Jones has served as Mereo’s Chief Financial Officer and as a member of the Mereo Board since January 2017. From 2011 until joining Mereo, Mr. Jones was the Chief Financial Officer and Company Secretary of Shield Therapeutics plc, where he also served as a Non-Executive Director from 2010 to 2011. Mr. Jones serves as a non-executive director on the board of Alliance Pharma plc. Mr. Jones is a qualified chartered accountant ACA with the Institute of Chartered Accountants in England and Wales (ICAEW) and holds a B.Eng. (Hons.) from the University of Newcastle upon Tyne.